M. Hersh

发表

Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.

D. V. Von Hoff, J. Kuhn, D. Boldt, 1984, Cancer research.

The Effect of 1-@-D-Arabinofuranosylcytosine on the Immune Response of Mice to Sheep Red Blood Cells1

E. Harris, M. Hersh, Evan, 2006 .

Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).

D. V. Von Hoff, G. Clark, T. F. Patton, 1985, Cancer research.

Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.

D. V. Von Hoff, G. Clark, J. Hutton, 1984, Cancer research.

Pharmacokinetic study of fludarabine phosphate (NSC 312887)

G. Clark, T. Ludden, J. Kuhn, 1986, Cancer Chemotherapy and Pharmacology.

Electrocardiographic monitoring of patients receiving phase I cancer chemotherapy.

D. V. Von Hoff, W. Linn, J. Kuhn, 1986, Cancer treatment reports.

Pharmacokinetics of high dose melphalan

W. Knight, T. Ludden, J. Kuhn, 1983, Investigational New Drugs.

A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer

G. Weiss, T. Ludden, J. Kuhn, 1985, Cancer Chemotherapy and Pharmacology.

Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion.

C. Coltman, G. Weiss, G. Clark, 1989, European journal of cancer & clinical oncology.

Inhibition of human lymphoma cell‐line colony formation by lymphocytes from patients with lymphoma and cancer hospital employees

E. Hersh, B. Drewinko, E. Taylor, 1976, Cancer.

High-performance liquid chromatographic assay for etoposide in human plasma.

T. Ludden, M. Hersh, 1986, Journal of pharmaceutical sciences.